Spatiotemporal distribution of community-acquired phenotypic extended-spectrum beta-lactamase Escherichia coli in United States counties, 2010-2019

Matthew W Smith; Margaret Carrel; Qianyi Shi; Shinya Hasegawa; Gosia Clore; Zhuo Tang; Eli Perencevich; Michihiko Goto

doi:10.1017/ice.2023.266

Spatiotemporal distribution of community-acquired phenotypic extended-spectrum beta-lactamase Escherichia coli in United States counties, 2010-2019

Infect Control Hosp Epidemiol. 2024 Apr;45(4):540-542. doi: 10.1017/ice.2023.266. Epub 2023 Dec 11.

Authors

Matthew W Smith^{1

2

3}, Margaret Carrel⁴, Qianyi Shi^{1

3}, Shinya Hasegawa^{1

2

3}, Gosia Clore^{1

3}, Zhuo Tang⁴, Eli Perencevich¹, Michihiko Goto^{1

2

3}

Affiliations

¹ Center for Access & Delivery Research and Evaluation (CADRE), Iowa City Veterans' Affairs Health Care System, Iowa City, Iowa.
² Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.
³ Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.
⁴ Department of Geographical and Sustainability Sciences, College of Liberal Arts and Sciences, University of Iowa, Iowa City, Iowa.

Abstract

Using data from the Veterans' Health Administration from 2010 to 2019, we examined the distribution and prevalence of community-acquired phenotypic extended-spectrum β-lactamase (ESBL) E. coli in the United States. ESBL prevalence slowly increased during the study period, and cluster analysis showed clustering in both urban and rural locations.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Cluster Analysis
Community-Acquired Infections* / drug therapy
Community-Acquired Infections* / epidemiology
Escherichia coli
Escherichia coli Infections* / drug therapy
Escherichia coli Infections* / epidemiology
Humans
Prevalence
beta-Lactamases

Substances

beta-Lactamases
Anti-Bacterial Agents